dihydrouracil has been researched along with Colorectal Cancer in 12 studies
hexahydropyrimidine-2,4-dione: structure in first source
5,6-dihydrouracil : A pyrimidine obtained by formal addition of hydrogen across the 5,6-position of uracil.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 9.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 7.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 7.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 7.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 6.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 5.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 5.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 3.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 3.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 3.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 2.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 1.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, W | 1 |
| Li, Y | 1 |
| Feng, Y | 1 |
| Yang, F | 1 |
| Liu, H | 1 |
| Jacobs, BAW | 1 |
| Snoeren, N | 1 |
| Samim, M | 1 |
| Rosing, H | 1 |
| de Vries, N | 1 |
| Deenen, MJ | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| Koopman, M | 1 |
| van Hillegersberg, R | 1 |
| Kobuchi, S | 3 |
| Ito, Y | 3 |
| Okada, K | 3 |
| Imoto, K | 3 |
| Kuwano, S | 3 |
| Takada, K | 3 |
| Nishimura, A | 1 |
| Shibata, N | 1 |
| Carlsson, G | 2 |
| Odin, E | 2 |
| Gustavsson, B | 2 |
| Wettergren, Y | 2 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| Guchelaar, HJ | 1 |
| van Kuilenburg, AB | 1 |
| Maring, JG | 1 |
| Gelderblom, H | 1 |
| Ben Fredj, R | 1 |
| Gross, E | 1 |
| Ben Ahmed, S | 1 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Morel, A | 1 |
| Boisdron-Celle, M | 2 |
| Fey, L | 1 |
| Lainé-Cessac, P | 1 |
| Gamelin, E | 2 |
| Zhou, ZW | 1 |
| Wang, GQ | 1 |
| Wan, de S | 1 |
| Lu, ZH | 1 |
| Chen, YB | 1 |
| Li, S | 1 |
| Chen, G | 1 |
| Pan, ZZ | 1 |
| Guérin-Meyer, V | 1 |
| Delva, R | 1 |
| Lortholary, A | 1 |
| Genevieve, F | 1 |
| Larra, F | 1 |
| Ifrah, N | 1 |
| Robert, J | 1 |
3 trials available for dihydrouracil and Colorectal Cancer
| Article | Year |
|---|---|
The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2018 |
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2007 |
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chi-Square Distribution; Chromatogra | 1999 |
9 other studies available for dihydrouracil and Colorectal Cancer